Search or
𝛼SK
𝛼SKbearish
M3：新型コロナウイルス関連の治験とワクチン接種プログラムが利益を牽引、中核事業の成長は鈍化
362 Views03 Feb 2022 02:51
m3の2022年度第3四半期の業績は、新型コロナウイルス感染症関連の臨床試験とワクチン接種プロジェクトによって牽引されましたが、これらはパンデミックの終息に伴い終了する予定です。コアビジネスは減速しており、m3は…を発表しました。
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Lepu Biopharma IPO: PHIP Updates09 Feb 2022
- MicroPort NeuroTech IPO: Impressive Product Portfolio Offsets Profitability Concerns07 Feb 2022
- Takeda: Key Drugs Continue Growth and Upgrade to Guidance; Pipeline Progress Despite Recent Setbacks03 Feb 2022
- Hoya: Life Care Exceeds Pre-Covid Levels; Slight Upgrade to Forecasts with a Small Buyback01 Feb 2022
- M3: Share Price Heading into a Correction and Further 20-25% Downside Likely22 Dec 2021
- M3: Strong 2Q Results but Earnings Growth Starts Decelerating28 Oct 2021
x